DARPA Seeks Partners to Support Hemorrhage Countermeasure Development

The Biological Technologies Office of the Defense Advanced Research Projects Agency (DARPA) issued a request for information, seeking input from industry and academia on capabilities related to hemorrhage countermeasure development. 

DARPA is specifically interested in partners that can provide independent verification and validation, clinical trial support and commercialization expertise. The agency aims to identify organizations capable of conducting third-party assessments of safety and efficacy while guiding products from research and development through regulatory approval and market transition. This request is for information gathering and program planning only and does not constitute a funding opportunity. 

DARPA noted that respondents able to address these domains in an integrated manner are of particular interest, as a single provider with comprehensive oversight could improve efficiency and better align data, regulatory strategy and commercialization pathways for both civilian and government applications. 

The response deadline is 4 p.m. ET on May 4.